Comparison of the Effects of Pioglitazone and Metformin on Hepatic and Extra-Hepatic Insulin Action in People With Type 2 Diabetes
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—To determine mechanisms by which pioglitazone and metformin effect hepatic and extra-hepatic insulin action. RESEARCH DESIGN AND METHODS—Thirty-one subjects with type 2 diabetes were randomly assigned to pioglitazone (45 mg) or metformin (2,000 mg) for 4 months. RESULTS—Glucose was clamped before and after therapy at ∼5 mmol/l, insulin raised to ∼180 pmol/l, C-peptide suppressed with somatostatin, glucagon replaced at ∼75 pg/ml, and glycerol maintained at ∼200 mmol/l to ensure comparable and equal portal concentrations on all occasions. Insulin-induced stimulation of glucose disappearance did not differ before and after treatment with either pioglitazone (23 ± 3 vs. 24 ± 2 μmol · kg−1 · min−1) or metformin (22 ± 2 vs. 24 ± 3 μmol · kg−1 · min−1). In contrast, pioglitazone enhanced (P < 0.01) insulin-induced suppression of both glucose production (6.0 ± 1.0 vs. 0.2 ± 1.6 μmol · kg−1 · min−1) and gluconeogenesis (n = 11; 4.5 ± 0.9 vs. 0.8 ± 1.2 μmol · kg−1 · min−1). Metformin did not alter either suppression of glucose production (5.8 ± 1.0 vs. 5.0 ± 0.8 μmol · kg−1 · min−1) or gluconeogenesis (n = 9; 3.7 ± 0.8 vs. 2.6 ± 0.7 μmol · kg−1 · min−1). Insulin-induced suppression of free fatty acids was greater (P < 0.05) after treatment with pioglitazone (0.14 ± 0.03 vs. 0.06 ± 0.01 mmol/l) but unchanged with metformin (0.12 ± 0.03 vs. 0.15 ± 0.07 mmol/l). CONCLUSIONS—Thus, relative to metformin, pioglitazone improves hepatic insulin action in people with type 2 diabetes, partly by enhancing insulin-induced suppression of gluconeogenesis. On the other hand, both drugs have comparable effects on insulin-induced stimulation of glucose uptake.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These actions modulate the transcription of genes with favorable effects on insulin sensitivity,13,36 fat distribution,37 plasma glucose,35,38 lipid and protein metabolism,36,38 vascular endothelial function,39 and inflammation.35,40”
From Pioglitazone after Ischemic Stroke or Transient Ischemic Attack (2016) · cites this paper as [36]
Citations
Cites
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 2×
“Previous studies have shown that thiazolidinediones and metformin inhibit multiple enzymes in the gluconeogenic pathway and when compared to placebo, lower gluconeogenesis in humans (9,10,12-15,43).”
BackgroundResult(1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-3-486_3 · Cited by 2,056
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., & Gerich, J. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330903 · Cited by 1,148 · cited 1×
“The relative ability of these agents to modulate hepatic and extra-hepatic insulin action is uncertain because most studies have compared the effects of a thiazolidinedione or metformin with that observed during treatment with placebo (14,19,21,26–31) or before treatment (13,15,16,18) rather than to one another.”
BackgroundKirpichnikov, D., McFarlane, S. I., & Sowers, J. R. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00009 · Cited by 1,084
Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review
Inzucchi, S. E. (2002) · JAMA · doi:10.1001/jama.287.3.360 · Cited by 1,065
Mechanism by which metformin reduces glucose production in type 2 diabetes.
Hundal, R. S., Krssak, M., Dufour, S., Laurent, D., Lebon, V, Chandramouli, V, Inzucchi, S. E., Schumann, W. C., Petersen, K. F., Landau, B. R., et al. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2063 · Cited by 1,052
Self-citationFryer, L. G. D., Parbu-Patel, A., & Carling, D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202489200 · Cited by 1,029
Measurement of Size and Turnover Rate of Body Glucose Pool by the Isotope Dilution Method
Steele, R., Wall, J. S., de Bodo, R. C., & Altszuler, N. (1956) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1956.187.1.15 · Cited by 816
Miyazaki, Y., Mahankali, A., Matsuda, M., Mahankali, S., Hardies, J., Cusi, K., Mandarino, L. J., & DeFronzo, R. A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.6.8567 · Cited by 726
Dose-response characteristics for effects of insulin on production and utilization of glucose in man
Rizza, R. A., Mandarino, L. J., & Gerich, J. E. (1981) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1981.240.6.e630 · Cited by 703
Self-citationTiikkainen, M., Häkkinen, A.-M., Korsheninnikova, E., Nyman, T., Mäkimattila, S., & Yki-Järvinen, H. (2004) · Diabetes · doi:10.2337/diabetes.53.8.2169 · Cited by 524 · cited 4×
“To our knowledge, the exception is the recent study by Tikkainen et al (32).”
BackgroundResultInfluentialEfficacy of Metformin in Type II Diabetes
Garber, A. J., Duncan, T. G., Goodman, A. M., Mills, D. J., & Rohlf, J. L. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00254-4 · Cited by 519
Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects
DEFRONZO, R. A., BARZILAI, N., & SIMONSON, D. C. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-6-1294 · Cited by 408
Miyazaki, Y., Mahankali, A., Matsuda, M., Glass, L., Mahankali, S., Ferrannini, E., Cusi, K., Mandarino, L. J., & DeFronzo, R. A. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.710 · Cited by 407
Natali, A., & Ferrannini, E. (2006) · Diabetologia · doi:10.1007/s00125-006-0141-7 · Cited by 377
Yki‐Järvinen, H. (1992) · Endocrine Reviews · doi:10.1210/er.13.3.415 · Cited by 368
Initial management of glycemia in type 2 diabetes mellitus
Nathan, D. M. (2002) · New England Journal of Medicine · doi:10.1056/nejmcp021106 · Cited by 359
Jensen, M., Kanaley, J., Reed, J., & Sheedy, P. (1995) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/61.2.274 · Cited by 344
A microfluorometric method for the determination of free fatty acids in plasma
Miles, J., Glasscock, R., Aikens, J., Gerich, J., & Haymond, M. (1983) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38029-9 · Cited by 329
The effects of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects
Chen, X., Iqbal, N., & Boden, G. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5479 · Cited by 291
Miyazaki, Y., Glass, L., Triplitt, C., Matsuda, M., Cusi, K., Mahankali, A., Mahankali, S., Mandarino, L. J., & DeFronzo, R. A. (2001) · Diabetologia · doi:10.1007/s001250100031 · Cited by 274
Mechanisms of Early Insulin-Sensitizing Effects of Thiazolidinediones in Type 2 Diabetes
Tonelli, J., Li, W., Kishore, P., Pajvani, U. B., Kwon, E., Weaver, C., Scherer, P. E., & Hawkins, M. (2004) · Diabetes · doi:10.2337/diabetes.53.6.1621 · Cited by 250
Khan, M. A., St. Peter, J. V., & Xue, J. L. (2002) · Diabetes Care · doi:10.2337/diacare.25.4.708 · Cited by 250
Modulation of Circulating and Adipose Tissue Adiponectin Levels by Antidiabetic Therapy
Phillips, S. A., Ciaraldi, T. P., Kong, A. P. S., Bandukwala, R., Aroda, V., Carter, L., Baxi, S., Mudaliar, S. R., & Henry, R. R. (2003) · Diabetes · doi:10.2337/diabetes.52.3.667 · Cited by 226
Hyperglycemia Decreases Glucose Uptake in Type I Diabetes
Yki-Järvinen, H., Helve, E., & Koivisto, V. A. (1987) · Diabetes · doi:10.2337/diab.36.8.892 · Cited by 205
Basu, R., Chandramouli, V., Dicke, B., Landau, B., & Rizza, R. (2005) · Diabetes · doi:10.2337/diabetes.54.7.1942 · Cited by 189
Self-citationBoden, G., Chen, X., Capulong, E., & Mozzoli, M. (2001) · Diabetes · doi:10.2337/diabetes.50.4.810 · Cited by 175
Mechanism of improvement in glucose metabolism after chronic glyburide therapy
Simonson, D. C., Ferrannini, E., Bevilacqua, S., Smith, D., Barrett, E., Carlson, R., & DeFronzo, R. A. (1984) · Diabetes · doi:10.2337/diabetes.33.9.838 · Cited by 166
Hällsten, K., Virtanen, K. A., Lönnqvist, F., Sipilä, H., Oksanen, A., Viljanen, T., Rönnemaa, T., Viikari, J., Knuuti, J., & Nuutila, P. (2002) · Diabetes · doi:10.2337/diabetes.51.12.3479 · Cited by 165
Johnson, A. B., Webster, J. M., Sum, C. F., Heseltine, L., Argyraki, M., Cooper, B. G., & Taylor, R. (1993) · Metabolism · doi:10.1016/0026-0495(93)90284-u · Cited by 164
Pavo, I., Jermendy, G., Varkonyi, T. T., Kerenyi, Z., Gyimesi, A., Shoustov, S., Shestakova, M., Herz, M., Johns, D., Schluchter, B. J., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021786 · Cited by 163
Ye, J.-M., Dzamko, N. L., Cleasby, M. E., Hegarty, B. D., Furler, S. M., Cooney, G. J., & Kraegen, E. W. (2004) · Diabetologia · doi:10.1007/s00125-004-1436-1 · Cited by 151
Fulgencio, J.-P., Kohl, C., Girard, J., & Pégorier, J.-P. (1996) · Diabetes · doi:10.2337/diab.45.11.1556 · Cited by 129
Ciaraldi, T. P., Kong, A. P. S., Chu, N. V., Kim, D. D., Baxi, S., Loviscach, M., Plodkowski, R., Reitz, R., Caulfield, M., Mudaliar, S., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.1.30 · Cited by 128
Pioglitazone Increases Insulin Sensitivity by Activating Insulin Receptor Kinase
Kobayashi, M., Iwanishi, M., Egawa, K., & Shigeta, Y. (1992) · Diabetes · doi:10.2337/diab.41.4.476 · Cited by 127
Firth, R. G., Bell, P. M., & Rizza, R. A. (1986) · New England Journal of Medicine · doi:10.1056/nejm198605153142003 · Cited by 121
Self-citationMetformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes
Hother-Nielsen, O., Schmitz, O., Andersen, P. H., Beck-Nielsen, H., & Pedersen, O. (1989) · Acta Endocrinologica · doi:10.1530/acta.0.1200257 · Cited by 117
Matthaei, S., Hamann, A., Klein, H. H., Benecke, H., Kreymann, G., Flier, J. S., & Greten, H. (1991) · Diabetes · doi:10.2337/diab.40.7.850 · Cited by 113
Inhibition of hepatic gluconeogenesis by metformin
Wollen, N., & Bailey, C. J. (1988) · Biochemical Pharmacology · doi:10.1016/0006-2952(88)90617-x · Cited by 111
Nosadini, R., Avogaro, A., Trevisan, R., Valerio, A., Tessari, P., Duner, E., Tiengo, A., Velussi, M., Del Prato, S., De Kreutzenberg, S., et al. (1987) · Diabetes Care · doi:10.2337/diacare.10.1.62 · Cited by 109
Karlsson, H. K. R., Hällsten, K., Björnholm, M., Tsuchida, H., Chibalin, A. V., Virtanen, K. A., Heinonen, O. J., Lönnqvist, F., Nuutila, P., & Zierath, J. R. (2005) · Diabetes · doi:10.2337/diabetes.54.5.1459 · Cited by 93
The Effect of Pioglitazone on the Liver
Gastaldelli, A., Miyazaki, Y., Mahankali, A., Berria, R., Pettiti, M., Buzzigoli, E., Ferrannini, E., & DeFronzo, R. A. (2006) · Diabetes Care · doi:10.2337/dc05-2445 · Cited by 86
The Effect of Rosiglitazone on the Liver: Decreased Gluconeogenesis in Patients with Type 2 Diabetes
Gastaldelli, A., Miyazaki, Y., Pettiti, M., Santini, E., Ciociaro, D., DeFronzo, R. A., & Ferrannini, E. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1159 · Cited by 75
Fruehwald‐Schultes, B., Oltmanns, K. M., Toschek, B., Sopke, S., Kern, W., Jan Born, A., Fehm, H. L., & Peters, A. (2002) · Metabolism · doi:10.1053/meta.2002.31332 · Cited by 68
Hyperglycemia decreases glucose uptake in type I diabetes
Yki‐Järvinen, H., Helve, E., & Koivisto, V. A. (1987) · Diabetes · doi:10.2337/diabetes.36.8.892 · Cited by 49
Pioglitazone increases insulin sensitivity by activating insulin receptor kinase
Kobayashi, M., Iwanishi, M., Egawa, K., et al. (1992) · Diabetes · doi:10.2337/diabetes.41.4.476 · Cited by 47
Determination of the Enrichment of the Hydrogen Bound to Carbon 5 of Glucose on 2H2O Administration
Schumann, W. C., Gastaldelli, A., Chandramouli, V., Previs, S. F., Pettiti, M., Ferrannini, E., & Landau, B. R. (2001) · Analytical Biochemistry · doi:10.1006/abio.2001.5326 · Cited by 38
Self-citationTonelli, J., Li, W., Kishore, P., Pajvani, U. B., Kwon, E.-H., Weaver, C. L., Scherer, P. E., & Hawkins, M. (2005) · Diabetes · Cited by 36
Fulgencio, J.-P., Kohl, C., Girard, J. R., et al. (1996) · Diabetes · doi:10.2337/diabetes.45.11.1556 · Cited by 34
Baptista, T., Sandia, I., Lacruz, A., Rangel, N., Mendoza, S. D., Beaulieu, S., Contreras, Q., Galeazzi, T., & Vargas, D. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32801182e6 · Cited by 32
Metformin effects on peripheral sensitivity to insulin in non diabetic obese subjects.
Fendri, S., Debussche, X., Puy, H., Osunkalu Vincent, O., Marcelli, J. M., Dubreuil, A., & Lalau, J. D. (1993) · PubMed · Cited by 15
Cunha, M. R., Silva, M. E. R. D., Machado, H. A., Fukui, R. T., Correa, M., Santos, R. F., WAJCHENBERG, B. L., Rondon, M. U. P. B., Negrão, C. E., & Ursich, M. J. M. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02117.x · Cited by 13
Research works printed but not linked: 1
- Buse JB, Polonsky KS, Burant CF: Chapter 29: Type 2 Diabetes Mellitus. In Larsen:Williams Textbook of Endocrinology, 10th ed. Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, Eds. Philadelphia, PA, Saunders,2003, p.1427–1482
Cited by
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
Kernan, W. N., Viscoli, C. M., Furie, K. L., Young, L. H., Inzucchi, S. E., Gorman, M., Guarino, P. D., Lovejoy, A. M., Peduzzi, P. N., Conwit, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506930 · Cited by 1,124
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub4 · Cited by 893
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub3 · Cited by 434
Häring, H.-U., Merker, L., Seewaldt-Becker, E., Weimer, M., Meinicke, T., Broedl, U. C., Woerle, H. J., & on behalf of the EMPA-REG MET Trial Investigators (2014) · Diabetes Care · doi:10.2337/dc13-2105 · Cited by 400
Packer, M. (2020) · Circulation: Heart Failure · doi:10.1161/circheartfailure.120.007197 · Cited by 176
Metadata
- Authors
- Basu, R., Shah, P., Basu, A., Norby, B., Dicke, B., Chandramouli, V., Cohen, O., Landau, B. R., & Rizza, R. A.
- Affiliations
- Mayo Clinic (US)
- The University of Texas MD Anderson Cancer Center (US)
- Case Western Reserve University (US)
- Sheba Medical Center (IL)
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2008-01-01
- Volume
- 57
- Issue
- 1
- Pages
- 24-31
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2156803989
- Cited by
- 63
- References
- 49
- Citations by year
- 2026: 2 · 2025: 1 · 2023: 6 · 2022: 2 · 2021: 5 · 2020: 3 · 2019: 2 · 2018: 3 · 2017: 2 · 2016: 4 · 2015: 2 · 2014: 3 · 2013: 3 · 2012: 2
- FWCI
- 5.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Mayo Clinic
- U.S. Public Health Service
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-14507, DK 29953)
- National Center for Research Resources (RR-00585, U 54RR 24150-1, M01RR000585)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- pioglitazone, metformin, type 2 diabetes, insulin action, hepatic insulin action, glucose production, gluconeogenesis, free fatty acids, insulin sensitivity, thiazolidinediones, glucose clamp, C-peptide, glucagon, glycerol infusion, insulin resistance, antidiabetic drugs
- MeSH terms
- Pioglitazone, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Diet, Diabetic, Double-Blind Method, Drug Administration Schedule, Fatty Acids, Nonesterified, Female, Glucagon, Gluconeogenesis, Glycerol, Humans, Hypoglycemic Agents, Infusions, Intravenous, Insulin, Kinetics, Liver, Male, Metformin, Middle Aged, Placebos, Glucose Clamp Technique, Body Mass Index, Thiazolidinediones, Glycogenolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.